THTX

NASDAQ

Theratechnologies Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

$3.40+0.01 (+0.30%)

News25/Ratings2

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

News · 26 weeks10%

2025-10-262026-04-19

Mix090d

No activity.

Latest news

25 items

160dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.
SCHEDULE 13G/A - Theratechnologies Inc. (0001512717) (Subject)
210dSEC
SEC Form 25-NSE filed by Theratechnologies Inc.
25-NSE - Theratechnologies Inc. (0001512717) (Subject)
210dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
210dPR
Theratechnologies Announces Completion of Acquisition by Future Pak
MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today the completion of the previously-announced plan of arrangement under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"), pursuant to which the Purchaser has acquired all the issued and outstanding common shares of the Company (the "Shares") for US$3.01 per Share in cash plus one contingent value right ("CVR") per Share for additional aggregate cash payments of up to US$1.19 per CVR if
218dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
219dPR
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
MONTREAL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that the Company has obtained the final order from the Superior Court of Québec (Commercial Division) approving the previously-announced plan of arrangement (the "Arrangement") under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"). This final court approval follows the approval of the Arrangement by the shareholders of the Company at the special meeting of shareholders held on Septe
223dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
223dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
223dPR
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement (the "Arrangement") under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the "Purchaser"), an affiliate of Future Pak, LLC ("Future Pak"). At the special meeting of shareholders of Theratechnologies held earlier today, the arrangement resolution was approved by 97.44% of the votes cast by the holders of shares present in person or virtually or represented by
230dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
230dPR
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
EGRIFTA WR™ offers convenience of weekly reconstitution and reduced daily injection volume, compared to EGRIFTA SV® Specialty pharmacies are now ordering EGRIFTA WR™ to fill prescriptions MONTREAL, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the availability of EGRIFTA WR™ (tesamorelin) for injection for the reduction of excess abdominal fat in adult patients with HIV and lipodystrophy. The announcement follows the approval of EGRIFTA WR™ by the U.S. Food and Drug Administration (FDA) earlier this year. "Excess visceral abdominal fat is an increasin
233dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
233dPR
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote "FOR" the Proposed Plan of Arrangement with Future Pak
Your vote is important regardless of the number of Shares you own.Board unanimously recommends shareholders vote "FOR" the Arrangement.Shareholders are encouraged to review the circular carefully and submit their proxies in advance of the proxy voting deadline of 10:00 a.m. (Eastern time) on September 10, 2025.Visit www.theratech.com for more information.Questions or require voting assistance? Contact Laurel Hill Advisory Group at 1-877-452-7184 or email assistance@laurelhill.com. MONTREAL, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that two
248dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
248dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
248dPR
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak's initial non-binding proposal.Board unanimously recommends shareholders vote "FOR" the Arrangement.Shareholders are encouraged to review the circular carefully and submit their proxies in advance of the proxy voting deadline of 10:00 a.m. (Eastern time) on September 10, 2025.Visit www.theratech.com for more information.Questions or require votin
261dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.
SCHEDULE 13G/A - Theratechnologies Inc. (0001512717) (Subject)
268dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.
SCHEDULE 13G/A - Theratechnologies Inc. (0001512717) (Subject)
279dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
287dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
288dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
288dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
288dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
288dSEC
SEC Form 6-K filed by Theratechnologies Inc.
6-K - Theratechnologies Inc. (0001512717) (Filer)
288dPR
Theratechnologies Reports Financial Results for the Second Quarter 2025
Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the second quarter 2025, ended May 31, 2025. All figures are in U.S. dollars unless otherwise stated. "Demand for EGRIFTA SV® remains very strong and we are witnessing